Search results: (10000)
News Less is Sometimes More – How Generic Substitution Can Affect Patient Adherence
It is undisputed that the use of generic drugs saves the healthcare system significant costs. Although doctors should certainly care about the health of the system, they primarily care for the health of individual patients – and for them, generic substitution may not always be the best choice. For instance, it is now known that it is not ideal for drugs with a narrow therapeutic range, such as antiepileptics, antidepressants, or antiparkinsonian drugs. But does this mean that generic substitution is always a welcome choice for other drugs?
News Cardio-renal-metabolic syndrome in context
The increase in the incidence of type 2 diabetes mellitus (T2DM), cardiovascular diseases (CVD), and chronic kidney disease (CKD) ranks among the most significant health issues of our time. Based on recent studies, these conditions are likely interconnected at various levels, whether in epidemiology, pathophysiology, or patient prognosis. Consequently, the term cardio-renal-metabolic syndrome (CRMS) has been defined.
News Thyroid Function During COVID-19 Illness and After Recovery
Acute infection with the SARS-CoV-2 coronavirus has varying impacts on different organ systems of the human body. Until now, it has not been certain how precisely it affects the endocrine system, especially the thyroid gland. The study presented below investigated how thyroid function changes in relation to the course of COVID-19 infection.
News Early Effect of Once-a-Day Trazodone in the Treatment of Major Depressive Disorder
Most antidepressants have a delayed onset of action, reaching therapeutically effective levels only several weeks after the start of treatment. Trazodone is characterized by a specific mechanism of action and a rapid onset of therapeutic effect. A newly published analysis evaluated the available clinical data regarding the early effect of once-a-day trazodone in patients with Major Depressive Disorder (MDD).
News Fixed Combination of Trastuzumab and Pertuzumab for Subcutaneous Administration in Patients with Early Breast Cancer
At a symposium focused on breast cancer, held in December 2019 in San Antonio, Texas, preliminary results of the FeDeriCa clinical study were presented – comparing the pharmacokinetics, efficacy, and safety of a fixed combination of trastuzumab and pertuzumab for subcutaneous administration versus intravenous administration in patients with early-stage HER2-positive breast cancer. Based on the presented results, the drug received approval from the U.S. Food and Drug Administration (FDA).
News How Does Cenobamate Compare with Third-Generation Anti-Seizure Medications in Terms of Cost-Effectiveness?
The main goal of epilepsy treatment is to achieve seizure freedom without unacceptable side effects of therapy. Despite the benefits of the latest generation of anti-seizure medications (ASMs), approximately 40% of patients suffer from drug-resistant epilepsy. The recently approved cenobamate brings new hope to patients. A Spanish pharmacoeconomic study aimed to compare the cost-effectiveness of cenobamate with selected third-generation ASMs as adjunctive therapy in patients with drug-resistant focal epilepsy.
News Generic Substitution of Levothyroxine in Practice
The active ingredient levothyroxine is found in a significant number of medicinal products (MP) in the Czech Republic. The question of its generic substitution remains current, primarily because the previously published data tend to call for caution due to possible adverse effects on the patient.
News Anxiety Disorders and Autoimmune Thyroiditis – A Connection Rather Than Coincidence?
Anxiolytics commonly target the central nervous system. Newly published research by Ukrainian authors offers a different perspective – according to their findings, anxiety may be related to thyroid inflammation.
News Hydrotherapy in the Treatment of Non-Healing Wounds
For the treatment of wounds, it is crucial how they are managed during the cleaning and granulation phases. For most non-healing wounds, so-called Hydrotherapy (treatment with hydroresponsive dressings) is suitable, which involves just two steps. The essence of Hydrotherapy is the maintenance of a moist environment and, if possible, a constant temperature in the wound.
News Teriflunomide in the Treatment of RRMS: The Best Working Drug Is the One That the Patient Actually Takes
Teriflunomide is an oral disease-modifying drug (DMD) used in the therapy of relapsing-remitting multiple sclerosis (RRMS). The authors of the cited American study assessed adherence to this treatment and subsequently the effect of adherence on the occurrence of RRMS relapses and the utilization of healthcare services during the first year following the initial prescription of teriflunomide.
News Intestinal Infection of Multi-Resistant NDM-Producing K. pneumoniae in a Patient with NK/T Lymphoma – Case Study
The incidence of NDM-producing Klebsiella pneumoniae is increasing worldwide. NDM beta-lactamase is a significant cause of multidrug resistance in enterobacteria to various antibiotics, including carbapenems. Currently, the most suitable approach for the treatment of intestinal infections caused by NDM-producing K. pneumoniae is considered to be the combination of ceftazidime/avibactam with aztreonam. The following case study also illustrates its use in more complicated cases.
News Advances in the Treatment of Myasthenia Gravis on the Horizon
The research of new drugs for the generalized form of myasthenia gravis has made significant progress in recent years. How is the new specific therapy performing? And are we heading towards a radical change in treatment strategy?
News Teriflunomide "under the microscope" or what it's like to live with MS in the North
The Teri-LIFE study examined teriflunomide very comprehensively. How does it manage to affect the quality of life of patients with multiple sclerosis (MS) according to data from real clinical practice in the Nordic countries? What is adherence to this therapy like? And what are its health-economic consequences? We briefly summarize the answers to these questions.
News Tailored Treatment. Who is Teriflunomide Suitable For?
The authors of the recently published study cited below not only focused on the safety and efficacy of teriflunomide in real-world clinical practice but also on the risk factors for its insufficient effectiveness. Who is teriflunomide most suitable for, and when should alternatives be considered?
News Cognitive changes in MS – what can teriflunomide do?
In Phase III clinical trials, teriflunomide demonstrated its ability to slow down brain tissue atrophy in patients with relapsing-remitting multiple sclerosis (RRMS). What impact did the treatment have on the cognitive state of these patients?